Question 1

A 28-year-old man with schizophrenia has been tried on risperidone 6mg for 8 weeks and olanzapine 20mg for 8 weeks, with only partial improvement in auditory hallucinations and persistent paranoid delusions on both. His psychiatrist is considering the next step. Which is the most appropriate recommendation?

Accepted Answer

This patient has failed two adequate antipsychotic trials at therapeutic doses for adequate duration. He meets the definition of treatment-resistant schizophrenia. The evidence-based next step is clozapine, not a third non-clozapine trial (answer A), combination antipsychotics (answer B, which lacks strong evidence and adds side effect burden), or augmentation of a medication that already failed (answer D). Delaying clozapine to try additional non-clozapine strategies is one of the most common errors in schizophrenia management and causes unnecessary suffering. With the 2025 elimination of the REMS program, the administrative barriers that previously deterred clinicians have been removed. ANC monitoring and metabolic surveillance remain necessary, but these are manageable clinical tasks, not bureaucratic obstacles.

Question 2

A patient has been stable on clozapine 400mg for 2 years. He is admitted to the hospital for pneumonia. He is a heavy smoker (1.5 packs/day) and the hospital is a smoke-free facility. On hospital day 3, the nurse reports that the patient is extremely sedated, confused, and drooling excessively. His blood pressure is 88/54 and his heart rate is 52. What is the most likely explanation?

Accepted Answer

This is the CYP1A2 smoking cessation emergency. Heavy smoking induces CYP1A2, which accelerates clozapine metabolism and keeps levels in the therapeutic range at 400mg. When the patient is admitted to a smoke-free hospital, CYP1A2 induction ceases within days. Clozapine levels rise as the enzyme activity normalizes, producing toxicity at the same dose that was previously safe. The symptoms (excessive sedation, hypotension, bradycardia, increased sialorrhea) are classic clozapine toxicity. The response: check a clozapine level, reduce the dose by approximately 30-50%, monitor closely, and plan for dose readjustment when the patient resumes smoking after discharge (levels will drop again and the dose may need to increase). This is the same CYP1A2 interaction taught on the olanzapine and duloxetine pages, but with clozapine the consequences are more dangerous because the therapeutic window is narrower.

Question 3

A patient on clozapine 350mg for treatment-resistant schizophrenia has her weekly ANC drawn. The result comes back at 900/mm3. Her previous ANC values have been consistently above 2000/mm3. She has no signs of infection. She does not have a documented history of benign ethnic neutropenia. What is the required action?

Accepted Answer

An ANC of 900/mm3 falls in the 500-999 range, which requires clozapine interruption (not permanent discontinuation). Daily ANC monitoring is initiated. Treatment may be resumed once the ANC recovers to 1000/mm3 or above, though the decision to rechallenge should involve careful risk-benefit analysis. Continuing treatment (answer A) is inappropriate because this ANC level warrants a hold per prescribing information guidelines. Permanent discontinuation (answer C) is too aggressive; the threshold for considering permanent discontinuation is ANC below 500/mm3. Dose reduction (answer D) is not the appropriate response; the issue is not dose-dependent but represents potential bone marrow suppression requiring complete medication hold. The patient must be counseled about infection precautions while neutropenic.

Clozapine

Side Effects Worth Knowing

Agranulocytosis/Severe Neutropenia: the defining monitoring requirement

Metabolic Syndrome: among the highest of any psychotropic

Myocarditis/Cardiomyopathy: rare but potentially fatal

Constipation/Ileus: potentially lethal

Sialorrhea: paradoxical drooling

Orthostatic Hypotension: alpha-1 mediated, worst during titration

Sedation: significant, often persistent

Tachycardia: common and often persistent

Seizures: dose-dependent

Weight Gain: among the most significant of any psychotropic

See This Medication in Action

References & Further Reading